Eloxx Pharmaceuticals, Inc. 8-K

What Happened

• Eloxx Pharmaceuticals, Inc. (ELOX) reported that on April 28, 2026 (Record Date) holders of 4,324,964 shares (57.1% of 7,573,935 outstanding shares) approved several stockholder actions by written consent.
• The approvals ratified a First Amendment to the company’s 2018 Equity Incentive Plan, authorized an amendment and restatement of that plan, authorized a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-20 (exact ratio to be set by the Board within one year), and approved a reduction in authorized common shares from 500,000,000 to 100,000,000 to be effected at the Board’s discretion within one year.
• The company filed a preliminary Schedule 14C on April 28, 2026 and said the actions will not become effective until a definitive information statement is mailed and at least 20 calendar days have passed (plus any other required steps).

Key Details

• Record Date: April 28, 2026; outstanding common shares entitled to vote: 7,573,935.
• Shares voting in favor: 4,324,964 (57.1%).
• Equity plan changes: increase shares available under the 2018 Plan to 20,000,000 and raise the incentive stock option (ISO) limit to 30,000,000; restatement extends ISO grant period, further increases ISO limit, extends evergreen provision, and adds administrative/clarifying amendments.
• Corporate charter changes: Board authorized to implement a reverse split between 1-for-2 and 1-for-20 and to reduce authorized common shares from 500,000,000 to 100,000,000, timing and exact split ratio to be set by the Board within one year.

Why It Matters

• Equity-plan increases and restatement mean the company can grant many more stock awards to employees, consultants, and directors, which can dilute existing shareholders if and when awards are issued.
• A reverse stock split (if implemented) will reduce the number of shares outstanding and raise the per-share price, which can affect trading liquidity and index/market listing considerations.
• Reducing authorized shares limits the maximum number of shares the company could issue in the future unless the charter is later amended again.
• None of the approved changes are yet effective: investors should watch for the definitive Schedule 14C mailing and the Board’s announcements about whether and when the reverse split or charter reduction will be implemented.